Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab in Children With Eosinophilic Diseases (CLIPS)
NCT06512883Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of benralizumab in eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), sponsored by AstraZeneca. Started Apr 2025; status: recruiting.
02
Drugs
benralizumab
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on NCT06512883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06512883.